GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Teva Pharma Industries Ltd ADR TEVA · USD

Health Care · US listing · 🇺🇸 United States

Compare

42.97

+0.84%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$17.26bn

FY2016FY2025

Net income

$1.41bn

FY2016FY2025

Free cash flow

$1.15bn

FY2016FY2025

Shareholders' equity

$7.91bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$17.26bn$16.54bn$15.85bn$14.93bn$15.88bn$16.66bn$16.89bn$18.85bn$22.39bn$21.90bn
Gross profit$8.94bn$8.06bn$7.64bn$6.97bn$7.59bn$7.73bn$7.54bn$8.30bn$10.82bn$11.86bn
Research and development$1.01bn$1.05bn$953.0m$838.0m$1.09bn$1.79bn$1.01bn$1.21bn$1.85bn$2.11bn
Operating income$2.16bn−$303.0m$433.0m−$2.18bn$1.63bn−$2.97bn$154.0m−$1.61bn−$17.51bn$1.37bn
Net income$1.41bn−$1.64bn−$559.0m−$2.45bn$417.0m−$3.99bn−$999.0m−$2.15bn−$16.27bn$329.0m
Diluted earnings per share1.20-1.45-0.49-2.200.38-3.60-0.91-2.09-15.990.32

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$40.75bn$39.33bn$43.48bn$44.01bn$47.67bn$50.64bn$57.47bn$60.68bn$70.61bn$92.89bn
Cash and short-term investments$3.56bn$3.30bn$3.23bn$2.80bn$2.17bn$2.18bn$1.98bn$1.78bn$963.0m$988.0m
Total liabilities$32.83bn$33.61bn$35.35bn$35.41bn$36.42bn$39.58bn$42.41bn$44.89bn$51.87bn$57.90bn
Debt$16.81bn$17.78bn$19.83bn$21.21bn$23.04bn$25.92bn$26.91bn$28.92bn$32.48bn$35.80bn
Shareholders' equity$7.91bn$5.37bn$7.51bn$7.80bn$10.28bn$10.03bn$13.97bn$14.71bn$17.36bn$33.34bn
Shares outstanding1,173m1,133m1,137m1,111m1,103m1,107m1,094m1,031m1,017m1,015m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$1.65bn$1.25bn$1.37bn$1.59bn$798.0m$1.22bn$538.0m$2.45bn$3.51bn$5.22bn
Capital spending−$501.0m−$498.0m−$526.0m−$548.0m−$562.0m−$578.0m−$119.0m−$651.0m−$874.0m−$901.0m
Free cash flow$1.15bn$749.0m$842.0m$1.04bn$236.0m$638.0m$419.0m$1.79bn$2.63bn$4.32bn
Dividends paid——————−$52.0m−$22.0m−$1.16bn−$1.56bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$4.14bn$3.98bn$4.71bn$4.48bn$4.18bn$3.89bn$4.23bn$4.33bn
Gross profit$2.15bn$1.97bn$2.66bn$2.30bn$2.10bn$1.88bn$2.12bn$2.15bn
Operating income$149.0m$652.0m$372.0m$882.0m$455.0m$519.0m−$29.0m−$51.0m
Net income−$576.0m$369.0m$480.0m$433.0m$282.0m$214.0m−$217.0m−$437.0m
Diluted earnings per share-0.490.310.410.370.240.18-0.19-0.39
Cash from operations$411.0m−$40.0m$1.16bn$369.0m$227.0m−$105.0m$575.0m$693.0m
Capital spending−$104.0m−$168.0m−$142.0m−$136.0m−$96.0m−$127.0m−$129.0m−$148.0m
Free cash flow$307.0m−$208.0m$1.02bn$233.0m$131.0m−$232.0m$446.0m$545.0m
Total assets$39.86bn$40.04bn$40.75bn$39.86bn$40.13bn$38.41bn$39.33bn$41.76bn
Cash and short-term investments$3.65bn$3.74bn$3.56bn$2.20bn$2.16bn$1.70bn$3.30bn$3.32bn
Debt$16.59bn$16.63bn$16.81bn$16.79bn$17.23bn$16.65bn$17.78bn$18.98bn
Shareholders' equity$7.76bn$8.23bn$7.91bn$7.25bn$6.83bn$6.26bn$5.37bn$6.07bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.0%0.7%-1.3%
Operating income——-4.3%
Net income——-1.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin50.3%49.0%48.3%49.2%
Operating margin5.5%0.2%-1.3%-7.9%
Net margin-0.7%-5.0%-7.0%-12.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings26.0-15.2-21.2-4.121.2-2.7-10.7-7.4-1.2111.8
Price to sales2.11.50.80.70.60.60.60.80.91.7

Market value over time

31 Mar 2016 to 18 Sept 2026, in USD

$49.23bn$46.04bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return43%99%24%7%-18%-3%-36%-9%-52%-44%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2-for-1 split · 1 Jul 2004
  • 2-for-1 split · 6 Dec 2002
  • 2-for-1 split · 23 Feb 2000
  • 5-for-3 split · 14 Apr 1993

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.